{ "schema": "peptency.research.regulatory/1", "description": "Regulator database records for each compound on the check date, with the source of each. A record is information, not legal advice.", "notice": "Research-use information. This library summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.", "checkedOn": "2026-10-05", "wadaListChecked": "2026-10-05", "sources": { "FDA": "openFDA Drugs@FDA (https://open.fda.gov/apis/drug/drugsfda/)", "EMA": "EMA medicines data, centrally authorised procedures (https://www.ema.europa.eu/en/medicines/download-medicine-data)", "MHRA": "MHRA Products, exact name search (https://products.mhra.gov.uk/)", "WADA": "WADA 2026 Prohibited List (https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf)" }, "overviewUrl": { "us": "https://peptency-528mygck1-wilcotds-projects.vercel.app/us/research/regulatory/", "eu": "https://peptency-528mygck1-wilcotds-projects.vercel.app/eu/research/regulatory/" }, "compounds": [ { "slug": "ghk-cu", "name": "GHK-Cu", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming prezatide or GHK as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names prezatide or copper tripeptide as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"prezatide\" or \"GHK-Cu\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "kpv", "name": "KPV", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming KPV as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names KPV as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"Lys-Pro-Val\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "bpc-157", "name": "BPC-157", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming BPC-157 or BPC 157 as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names BPC as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"BPC-157\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Named, S0", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 names BPC-157 under S0 (non-approved substances). A WADA entry is a sporting rule, not a statement about legality outside sport." } ] }, { "slug": "tb-500", "name": "TB-500", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming thymosin beta 4 or timbetasin or thymosin beta-4 as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names thymosin beta or timbetasin as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"thymosin beta 4\" or \"timbetasin\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Named, S2.3", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 names TB-500 under S2.3 (growth factors and growth factor modulators). A WADA entry is a sporting rule, not a statement about legality outside sport." } ] }, { "slug": "ipamorelin", "name": "Ipamorelin", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming ipamorelin as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names ipamorelin as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"ipamorelin\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Named, S2.2.4", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 names ipamorelin under S2.2.4 (growth hormone releasing factors,). A WADA entry is a sporting rule, not a statement about legality outside sport." } ] }, { "slug": "ghrp-2", "name": "GHRP-2", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming pralmorelin as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names pralmorelin as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"pralmorelin\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Named, S2.2.4", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 names GHRP-2 under S2.2.4 (growth hormone releasing factors,). A WADA entry is a sporting rule, not a statement about legality outside sport." } ] }, { "slug": "cjc-1295-no-dac", "name": "CJC-1295 no DAC", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming CJC-1295 as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names CJC-1295 as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"CJC-1295\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Named, S2.2.4", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 names CJC-1295 under S2.2.4 (growth hormone releasing factors,). A WADA entry is a sporting rule, not a statement about legality outside sport." } ] }, { "slug": "sermorelin", "name": "Sermorelin", "records": [ { "regulator": "FDA", "status": "2 applications listed (Discontinued)", "detail": "Drugs@FDA lists 2 applications naming this active ingredient: NDA019863, NDA020443. Marketing status as listed: Discontinued. Checked 2026-10-05." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names sermorelin as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"sermorelin\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Named, S2.2.4", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 names sermorelin under S2.2.4 (growth hormone releasing factors,). A WADA entry is a sporting rule, not a statement about legality outside sport." } ] }, { "slug": "tesamorelin", "name": "Tesamorelin", "records": [ { "regulator": "FDA", "status": "1 application listed (Prescription)", "detail": "Drugs@FDA lists 1 application naming this active ingredient: BLA022505. Marketing status as listed: Prescription. Checked 2026-10-05." }, { "regulator": "EMA", "status": "Application withdrawn", "detail": "EMA medicines database (checked 5 October 2026): application withdrawn for EMEA/H/C/002427 on 2012-06-21. Centrally authorised procedures only." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"tesamorelin\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Named, S2.2.4", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 names tesamorelin under S2.2.4 (growth hormone releasing factors,). A WADA entry is a sporting rule, not a statement about legality outside sport." } ] }, { "slug": "aod-9604", "name": "AOD-9604", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming AOD-9604 or AOD9604 as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names AOD9604 as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"AOD-9604\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Named, S2.2.3", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 names AOD-9604 under S2.2.3 (growth hormone (gh), its analogues and fragments). A WADA entry is a sporting rule, not a statement about legality outside sport." } ] }, { "slug": "mots-c", "name": "MOTS-c", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming MOTS-c as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names MOTS-c as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"MOTS-c\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Named, S4.4", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 names MOTS-c under S4.4 (metabolic modulators). A WADA entry is a sporting rule, not a statement about legality outside sport." } ] }, { "slug": "ss-31", "name": "SS-31", "records": [ { "regulator": "FDA", "status": "1 application listed (Prescription)", "detail": "Drugs@FDA lists 1 application naming this active ingredient: NDA215244. Marketing status as listed: Prescription. Checked 2026-10-05." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names elamipretide as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"elamipretide\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "nad-plus", "name": "NAD+", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming nadide or NAD as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names nadide or nicotinamide adenine dinucleotide as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"nadide\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "5-amino-1mq", "name": "5-Amino-1MQ", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming 5-amino-1MQ as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names 5-amino-1MQ as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"5-amino-1MQ\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "semaglutide", "name": "Semaglutide", "records": [ { "regulator": "FDA", "status": "6 applications listed (Prescription, Discontinued, None (Tentative Approval))", "detail": "Drugs@FDA lists 6 applications naming this active ingredient: NDA215256, NDA218316, NDA213051, NDA209637, NDA213182, ANDA220314. Marketing status as listed: Prescription, Discontinued, None (Tentative Approval). Checked 2026-10-05." }, { "regulator": "EMA", "status": "5 authorised", "detail": "EMA medicines database (checked 5 October 2026): 5 centrally authorised medicines (EMEA/H/C/005422, EMEA/H/C/004174, EMEA/H/C/004953, EMEA/H/C/006426, EMEA/H/C/006279). Centrally authorised procedures only." }, { "regulator": "MHRA", "status": "Product documents found (271)", "detail": "MHRA Products returns 271 SmPC, PIL or PAR documents for the exact name. Checked 2026-10-05." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "tirzepatide", "name": "Tirzepatide", "records": [ { "regulator": "FDA", "status": "2 applications listed (Prescription)", "detail": "Drugs@FDA lists 2 applications naming this active ingredient: NDA217806, NDA215866. Marketing status as listed: Prescription. Checked 2026-10-05." }, { "regulator": "EMA", "status": "1 authorised", "detail": "EMA medicines database (checked 5 October 2026): 1 centrally authorised medicine (EMEA/H/C/005620). Centrally authorised procedures only." }, { "regulator": "MHRA", "status": "Product documents found (106)", "detail": "MHRA Products returns 106 SmPC, PIL or PAR documents for the exact name. Checked 2026-10-05." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "retatrutide", "name": "Retatrutide", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming retatrutide as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names retatrutide as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"retatrutide\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "glutathione", "name": "Glutathione", "records": [ { "regulator": "FDA", "status": "Component of irrigation solutions only", "detail": "Drugs@FDA lists 2 applications for ophthalmic irrigation solutions that contain glutathione disulfide among several ingredients. None names glutathione as a peptide medicine (checked 2026-10-05)." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names glutathione as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "Name appears in text only", "detail": "The exact name returns 1092 MHRA Products documents; they mention the name in their text and were not assessed as products with it as an active substance. Checked 2026-10-05." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "ahk-cu", "name": "AHK-Cu", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming AHK-Cu as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names AHK as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"AHK-Cu\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "epitalon", "name": "Epitalon", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming epitalon or epithalon as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names epitalon as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"epitalon\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "thymosin-alpha-1", "name": "Thymosin α1", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming thymalfasin or thymosin alpha as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names thymalfasin or thymosin alpha as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"thymalfasin\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "selank", "name": "Selank", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming selank as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names selank as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"selank\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "semax", "name": "Semax", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming semax as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names semax as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"semax\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "dsip", "name": "DSIP", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming delta sleep-inducing peptide or DSIP as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names DSIP as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"delta sleep-inducing peptide\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "pt-141", "name": "PT-141", "records": [ { "regulator": "FDA", "status": "1 application listed (Prescription)", "detail": "Drugs@FDA lists 1 application naming this active ingredient: NDA210557. Marketing status as listed: Prescription. Checked 2026-10-05." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names bremelanotide as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"bremelanotide\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "melanotan-ii", "name": "Melanotan II", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming melanotan as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names melanotan as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "No product document found", "detail": "No SmPC, PIL or PAR document in MHRA Products matches the exact name \"melanotan\". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents." }, { "regulator": "WADA", "status": "Not named", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport." } ] }, { "slug": "kisspeptin-10", "name": "Kisspeptin-10", "records": [ { "regulator": "FDA", "status": "No application listed", "detail": "No application naming kisspeptin or metastin as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications." }, { "regulator": "EMA", "status": "No centrally authorised medicine listed", "detail": "No centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names kisspeptin as an active substance. National authorisations are not in this dataset." }, { "regulator": "MHRA", "status": "Name appears in text only", "detail": "The exact name returns 5 MHRA Products documents; they mention the name in their text and were not assessed as products with it as an active substance. Checked 2026-10-05." }, { "regulator": "WADA", "status": "Named, S2.2.1", "detail": "The WADA 2026 Prohibited List, in force 1 January 2026 names kisspeptin under S2.2.1 (testosterone-stimulating peptides in males). A WADA entry is a sporting rule, not a statement about legality outside sport." } ] } ] }